Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)

Ultragenyx Pharmaceutical (RARE) has disclosed Other financing activities for 5 consecutive years, with -$7.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Other financing activities fell 780.93% to -$7.0 million in Q4 2024 year-over-year; TTM through Sep 2024 was $8.0 million, a 5561.22% increase, with the full-year FY2023 number at $1.0 million, up 280.18% from a year prior.
  • Other financing activities was -$7.0 million for Q4 2024 at Ultragenyx Pharmaceutical, down from $7.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $7.0 million in Q3 2024 to a low of -$7.0 million in Q4 2024.
  • A 5-year average of -$16647.1 and a median of -$112000.0 in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: skyrocketed 963.87% in 2023, then tumbled 780.93% in 2024.
  • Ultragenyx Pharmaceutical's Other financing activities stood at -$87000.0 in 2020, then crashed by 63.22% to -$142000.0 in 2021, then grew by 16.2% to -$119000.0 in 2022, then surged by 963.87% to $1.0 million in 2023, then crashed by 780.93% to -$7.0 million in 2024.
  • Per Business Quant, the three most recent readings for RARE's Other financing activities are -$7.0 million (Q4 2024), $7.0 million (Q3 2024), and $1.0 million (Q4 2023).